Clinical trial
Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS…
NCT00195104 · Weill Medical College of Cornell University, Other · Completed
Key facts
| NCT number | NCT00195104 |
|---|---|
| Title | Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML |
| Official title | Phase I/II Study of Arsenic Trioxide in Combination With Cytosine Arabinoside in Patients With High-risk Myelodysplastic Syndrome and Poor-prognosis Acute Myelogenous Leukemia |
| Lead sponsor | Weill Medical College of Cornell University, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome |
| Intervention type | Drug |
| Interventions | Arsenic Trioxide (Tricenox), Cytarabine |
| Enrollment | 87 |
| Start date | Sep 17, 2003 |
| Primary completion | Mar 17, 2006 |
| Completion | Jun 20, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Mar 3, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: